PNC-27 is a laboratory-made protein fragment, never approved as a medicine, that is sold online and by clinics abroad as a cancer treatment. In laboratory dishes and mice it killed many cancer cells, but no study in people has tested whether it treats or prevents cancer. Products come from outside any regulated system, and real-world risks include contaminated products, possible serious bleeding and setting aside proven cancer care. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Hemoglobin | Men 13.2–16.6 g/dL; women 11.6–15.0 g/dL | Safety check: a fall signals bleeding |
| Platelets | 150–450 ×10⁹/L | Safety check: low counts raise bleeding risk |
| INR | 0.8–1.1 | Safety check: prolonged clotting raises bleeding risk |
| Potassium | 3.5–5.0 mmol/L | Safety check: a rise signals tumor lysis |
| Phosphate | 2.5–4.5 mg/dL | Safety check: a rise signals tumor lysis |
| Uric acid | 3.5–7.2 mg/dL | Safety check: a rise signals tumor lysis |
| Calcium | 8.6–10.3 mg/dL | Safety check: a fall signals tumor lysis |
| Creatinine | Men 0.74–1.35 mg/dL; women 0.59–1.04 mg/dL | Safety check: kidney injury from tumor lysis |
| LDH | 140–280 U/L | Expected to change: rises as cells burst; also a tumor lysis safety check |
| Cancer-specific tumor marker (e.g., CA-125, CEA, PSA) | No established target; change from own baseline | Expected to change if the tumor responds |
Cadence: Baseline before any use; electrolytes, uric acid and creatinine at 24–72 hours after the first dose and at 1 week; blood counts and chemistries every 2–4 weeks while in use; tumor markers and imaging typically every 2–3 months.